Analyst Ratings January 28, 2026

Truist Lifts Texas Instruments Price Target to $225, Keeps Hold Rating

Analysts broadly raise targets after TXN posts in-line quarter and issues above-seasonal guidance for Q1

By Caleb Monroe TXN
Truist Lifts Texas Instruments Price Target to $225, Keeps Hold Rating
TXN

Truist Securities increased its price target on Texas Instruments (TXN) to $225 from $195 while retaining a Hold rating, following the company's fourth-quarter results and a first-quarter guide that sits above seasonal norms. Multiple other brokerages also raised targets after the earnings and guidance, reflecting widespread analyst optimism even as firms caution that guidance may signal improvement rather than an outright inflection.

Key Points

  • Truist raised its TXN price target to $225 from $195 while keeping a Hold rating; the stock trades near a 52-week high and is up 13.34% year-to-date.
  • Texas Instruments’ Q4 results were described as "~inline," and the company guided Q1 approximately 2% above consensus, building on 13.05% revenue growth over the past twelve months; guidance is 3-4% above seasonal trends.
  • Several other brokerages increased their price targets following the earnings and guidance, with TD Cowen and KeyBanc to $240, Cantor Fitzgerald and Baird to $225, and Benchmark to $250; analysts cited stronger-than-expected guidance, favorable gross margins, and demand in data center and industrial end markets.

Truist Securities raised its price objective on Texas Instruments (NASDAQ:TXN) to $225.00 from $195.00 on Wednesday, but kept a Hold rating on the semiconductor manufacturer. The upgraded target arrives as TXN is trading close to its 52-week high of $221.69, with the stock up 13.34% year-to-date.

The firm said the price-target increase followed Texas Instruments’ fourth-quarter results, which Truist described as "~inline" with expectations. Management’s guidance for the first quarter came in at roughly 2% above consensus estimates and follows 13.05% revenue growth for the trailing twelve months, according to Truist’s note.

Truist drew attention to the company’s projection of quarter-over-quarter growth in the first quarter - an outcome the firm noted would occur for the first time in roughly 15 years. At the same time, Truist added context that Texas Instruments has delivered sequential growth in about half of the last 15 first-quarter periods, tempering the novelty of the development.

According to Truist, the company’s guidance sits 3-4% above normal seasonal patterns, a level the firm characterized as "good" and consistent with the fourth-quarter feedback Truist received from industry contacts. The firm framed this as "better than stabilization but not an inflection," signaling an improvement in momentum without treating the guidance as proof of a durable turnaround.

On longer-term estimates, Truist raised its calendar year 2027 earnings-per-share forecast for Texas Instruments to $7.50 from $7.06. The bank said its new $225 price target is based on a 30x multiple, which it described as representing a 3x discount to what it called "now-elevated peers."

Analyst actions at other firms following Texas Instruments’ earnings and guidance were broadly upward. TD Cowen boosted its price target to $240, citing the company’s first-quarter 2026 guidance that topped market expectations and pointed to an approximate gross margin of 57%.

KeyBanc also raised its target to $240, attributing the move to Texas Instruments’ in-line fourth-quarter results and strong demand in the data center and industrial sectors. Cantor Fitzgerald set a new target of $225, highlighting the company’s unexpectedly positive quarterly results and noting the first guidance for sequential growth in the first quarter since 2010.

Benchmark, which maintained a Buy rating, upped its target to $250 after Texas Instruments’ December quarter results met expectations and its March quarter guidance exceeded analyst projections. Baird increased its target to $225, calling the first-quarter outlook "above-seasonal, unit-driven" and surprising to investors.

These analyst moves illustrate a convergence of opinion around Texas Instruments’ recent results and the firmness of its near-term guidance, even as several firms stop short of declaring a full structural inflection. Truist’s retention of a Hold rating alongside a higher price target underscores that tension - a recognition of improved near-term dynamics while maintaining a cautious stance on valuation and longer-term trajectory.

Risks

  • Truist characterizes the company’s guidance as "better than stabilization but not an inflection," indicating risk that the above-seasonal guide may not mark a durable turnaround - this affects semiconductor industry outlook and related supply-chain demand.
  • Despite the higher price target, Truist maintained a Hold rating, which signals lingering caution around valuation or sustainability of improvement and represents a market risk for investors considering the stock.
  • The novelty of quarter-over-quarter growth in Q1 is tempered by Truist’s observation that Texas Instruments has delivered sequential growth in about half of the last 15 first-quarter periods, highlighting uncertainty about whether recent guidance represents a consistent pattern.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026